P1429: IN VITRO COMPARISON OF THE EFFECTS OF INCLACUMAB VS CRIZANLIZUMAB ON REDUCING ENDOTHELIAL ADHESION OF RED BLOOD CELLS IN STANDARDIZED MICROFLUIDIC PLATFORM
Chiara Federici,
Seniye Sertel,
Samantha Braxton,
Gabrielle Combs,
Madelyn Sphen,
Kara Ophein,
Pavel Kovshovik,
John Zak,
Xin Geng,
Umut Gurkan
Affiliations
Chiara Federici
1 BioChip Labs Inc, Cleveland, OH, United States
Seniye Sertel
1 BioChip Labs Inc, Cleveland, OH, United States
Samantha Braxton
1 BioChip Labs Inc, Cleveland, OH, United States
Gabrielle Combs
1 BioChip Labs Inc, Cleveland, OH, United States
Madelyn Sphen
1 BioChip Labs Inc, Cleveland, OH, United States
Kara Ophein
1 BioChip Labs Inc, Cleveland, OH, United States
Pavel Kovshovik
1 BioChip Labs Inc, Cleveland, OH, United States
John Zak
1 BioChip Labs Inc, Cleveland, OH, United States
Xin Geng
3 Global Blood Therapeutics, Inc., a wholly owned subsidiary of Pfizer Inc., South San Francisco, CA, United States
